ESMO

PRIMA Trial Finds QoL Not Reduced Despite Toxicities Observed in Patients with Gynecologic Malignancies
September 27, 2020

A subanalysis of the PRIMA/ENGOT-OV26/GOG-3012 trial found that quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo.

AUTO3, Pembrolizumab Combo Appears Safe, Elicits Durable Responses in Relapsed/Refractory DLBCL
September 27, 2020

Results from the phase 1/2 ALEXANDER study found the investigational CAR T-cell product AUTO3 in combination with pembrolizumab to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

PORT Not Recommended as Standard of Care for Completely Resected Stage IIIAN2 NSCLC
September 26, 2020

Post-operative radiotherapy was associated with a nonstatistically significant increase in disease-free survival in patients with completely resected stage IIIAN2 non-small cell lung cancer and therefore cannot be recommended as a standard of care.